Document is current

Article History

Received: 14 October 2024

Accepted: 5 February 2025

First Online: 11 February 2025

Declarations

:

: Not applicable.

: Not applicable.

: AS, EA, AD, IA, ED, BH, AI, RL, JP and AV declare that they have no competing interests. RBP is supported by grants from Fonds de la Recherche en Sante, grants from Canadian Institute of Health Research, the Michael J. Fox Foundation, the Webster Foundation, Roche, and the National Institute of Health; RBP reports personal fees from Takeda, Biogen, Abbvie, Curasen, Lilly, Novartis, Eisai, Paladin, Merck, Vaxxinity, Korro, Bristol Myers Squibb and the International Parkinson and Movement Disorders Society, outside the submitted work. MMTH is supported by grants from Parkinson’s UK, Oxford NIHR Biomedical Research Centre, University of Oxford, Michael J Fox Foundation, H2020 European Union and the PSP Association. She is an advisory founder of NeuHealth Digital Ltd (company number: 14492037), a digital biomarker platform to remotely manage condition progression for Parkinson’s disease. ZG received consultancy fees from Lysosomal Therapeutics Inc. (LTI), Idorsia, Prevail Therapeutics, Ono Therapeutics, Denali, Handl Therapeutics, Neuron23, Bial Biotech, Bial, UCB, Capsida, Vanqua bio, Congruence Therapeutics, Takeda, Jazz pharmaceuticals, Guidepoint, Lighthouse and Deerfield.